Gustave Roussy in Paris Links Up with New Oncology

October 14, 2014
Philip Ward

Philip Ward is ACT's European editor, phone +44 1244 538583, philipward1@btconnect.com

Applied Clinical Trials

New Oncology has entered into a research agreement with Gustave Roussy Cancer Campus in Paris.

New Oncology has entered into a research agreement with Gustave Roussy Cancer Campus in Paris.

Under this agreement, New Oncology will perform comprehensive parallel multigene testing to identify therapeutically relevant alterations in cancer-related genes. New Oncology will apply its proprietary diagnostic platform ‘NEO’, which allows sample processing compatible with both daily clinical routine and standard sample material, i.e. FFPE (formalin-fixed, paraffin-embedded) tissue, according to the company.

Gustave Roussy is an international institute in oncology with a staff of 2,600 health professionals. By devoting 20% of its budget to research, it aims to promote research as an innovative engine for the benefit of patients. Gustave Roussy is a private health facility working within the French public health system and is authorized to receive donations and bequests.

“The dramatic responses seen in patients receiving targeted treatment have shifted the therapeutic paradigm to therapies which are based on the molecular characteristics of a given cancer. Thus, comprehensive genomic diagnosis of FFPE tissues is an important step to optimize clinical care to patients throughout the different lines of therapy” said Prof. Jean-Charles Soria, Head of the Drug Development Department at Gustave Roussy Cancer Campus.

“We are very pleased to partner with Gustave Roussy, Europe’s leading oncology center. We look forward to contributing New Oncology’s unique diagnostic platform enabling in-depth genetic profiling of tumor samples. Together, we expect to significantly improve personalized approaches for the benefit of cancer patients” commented Andreas Jenne, PhD, CEO of New Oncology, the molecular diagnostics division of Blackfield AG, a company specializing in cancer genome analysis.

New Oncology’s proprietary diagnostic platform ‘NEO’ enables physicians to select the optimal targeted therapy for their patients, including participation in suitable clinical trials. Its pan-cancer diagnostic test NEOplus detects actionable genetic alterations with short turn-around times and identifies all types of therapeutically relevant alterations, i.e. mutations, amplifications, insertions/deletions, as well as novel and known translocations, from one single patient sample, according to the vendor. It works with a tumor board comprising renowned cancer experts, facilitating translation of the latest findings in targeted therapy into optimized patient care.

Read the full release here.

Related Content:

News